Abstract. Human immunoglobulins circulate as highly heterogeneously glycosylated mixture of otherwise homogeneous protein backbones. A series of studies, mainly on IgG, have unequivocally proven that antibodies modulate their effector function through sugars present in the Fc domain. However, our limited technology in producing complex proteins such as antibodies, with defined glycan structures hamper in depths studies. This review introduces a plant based expression platform enabling engineering of antibody glycans. The procedure is based on the simultaneous delivery of appropriate constructs, carrying cDNAs of target proteins (e.g. heavy and light chain of antibodies) in combination with human glycosylation enzymes into plant leaves. Harvesting of recombinant proteins one week post construct delivery allows high speed and flexibility. Major achievements include the production of functional active slialylated pentameric IgMs in tobacco leaves. The system provides a viable approach to the generation of antibodies with defined glycoforms on demand, contributing to studies on antibody glycans and the development of novel antibody based drugs.
Introduction
Plants are increasingly being used as an alternative expression system for human antibodies. A notable reason is their ability to correctly fold and assemble complex human proteins and carry out human type posttranslational modifications [1] . This holds particularly true for N-glycosylation, a modification extensively present in manifold variations on all immunoglobulins (Ig). It is well known that Ig circulate as a highly heterogeneously glycosylated mixture of otherwise homogeneous protein backbones. This micro heterogeneity is mainly owed to the differences in the content of sialic acid, galactose, core-fucose and bisecting N-acetylglucosamine (Gn) [2] . IgG, the simplest immunoglobulin isoform, contains one single Nglycosylation site in the constant domain, representing a conserved site in all Ig-classes. Glycosylation on IgG has been studied in various settings. It is now well established that the type of glycan present on FcIgG1 helps dictate the effector function of the antibody and are involved in the processing of pro-and anti-inflammatory properties [3] . However much less is known about carbohydrates of other immunoglobulins, which are by far more extensively glycosylated. This lack of knowledge is due in part to our current limitations in technology and the complexity of these glycosylated proteins. However, the discovery that the effector function of therapeutic antibodies can be increased by certain sugar profiles led to the development of expression platforms that facilitate the production of proteins with a designed glycosylation pattern [3] [4] [5] . Plants are particularly amenable to such glycan-engineering processes.
Elimination of plant specific N-glycans
Serum IgG-Fc-linked carbohydrates are complextype bi-antennary N-glycans with high levels of core α1,6-fucosylation (> 80%) and a variable number of galactose residues (Fig. 1A) [6, 7] . Striking differ-ences of plant and mammalian cell produced antibodies are (a) the presence of certain core plant specific modifications (i.e. β1,2-xylose and core α1,3-fucose), and (b) the lack of diversification of GnGn structures, the common core carbohydrate structure in eukaryotic cells. As a consequence plant proteins lack β1,4 galactose and sialic acid residues (Fig. 1A) . On the other side non mammalian core modifications of plant produced Igs might serve as an obstacle in therapeutic applications. Efforts to prevent the synthesis of these non-human residues have focused on inhibiting the respective enzymes (i.e. β1,2-xylosyltransferase and core α1,3-fucosyltransferase) by knock-down/-out strategies and, more recently, by chemical mutagenesis [8] . These efforts resulted in the generation of plant species that synthesize complex N-glycans composed of the GnGn oligosaccharide devoid of planttypical glycan residues in a number of plant species (A. thaliana, Nicotiana benthamiana, lemna, moss, rice) [9] [10] [11] [12] . This achievement was a milestone in glycan engineering approaches because it (i) demonstrated the plasticity of plants to tolerate manipulations of the N-glycosylation pathway without causing any obvious phenotype, (ii) generated the central acceptor substrate for further elongation steps, and (iii) enabled a significant increase in glycan homogeneity, which may have substantial implications for downstream processing and meets regulatory requirements for therapeutic proteins. Importantly, the absence of core fucose residues has placed plants in a particularly favorable position for developing next generation drugs, as therapeutic monoclonal antibodies produced in such glycosylation mutants have improved biological activities compared with those produced in CHO cells [11, 13, 14] , (see also Hiatt A., this issue).
Introduction of human glycans to plants
Interestingly plant and mammalian cells share a common machinery for the biosynthesis of N-glycans that is conserved up to the generation of GnGn structures in the Golgi apparatus. With a few exceptions further diversification of N-glycans is usually not accomplished in plants because they lack the necessary enzymatic catalogue. Approaches to augment plant glycosylation towards human-like structures have been based on the expression of human glycosyltransferases in plants and were first successfully applied by Palacpac [15] and Bakker [16] . The two groups generated β1,4-galactosylated IgG antibodies, the major glycan form in human serum, in tobacco by the overexpression of the human β1,4-galactosyltransferase. Consequently, work over the past decade on the controlled expression of mammalian GTs has established plantbased systems that enable the reconstruction of glycosylation profiles typically found on human serum antibodies, with the important difference, that these structures can be generated under controlled conditions in its single forms (Fig. 1B) . These include all major structures commonly found on serum IgG (i.e. mono and di-galactosylated, sialylated, and bisected structures, with and without fucosylation) (recently reviewed by [5, 8] ). Recent studies demonstrate that even entire human glycosylation-associated biosynthetic pathways can be transferred into plants. This has been shown by the introduction of the sialylation pathway and the pathway for mucin-type O-glycans in Nicotiana benthamiana, a tobacco related plant species frequently used for antibody expression [17, 18] . Remarkably, plants did not exhibit phenotypic alterations despite extensive glycan manipulation processes. The ability to generate human antibodies with a controlled sialylation pattern is of special interest since all antibody classes except IgG are heavily decorated with this complex glycosylation pattern. Little knowledge is available about the impact of sialylated structures on the function of antibodies other than IgG; only one study reports the importance of sialylated N-glycans in inducing the IgM-mediated immune suppression [19] . In fact a lively discussion about the anti-inflammatory potency of sialylated IgG-Fc is ongoing [20, 21] . However mainly due to different experimental settings the obtained data are difficult to compare. The ability to generate antibodies with a controlled sialylation profile in plants now facilitates follow up experiments in this context.
Glycan engineering by a transient expression approach
Glycan-engineering approaches in plants are traditionally based on the stable integration of glycanmodifying cDNA constructs into the genome, which is a time intensive procedure [7, 15, 16, [22] [23] [24] . More recently a transient expression system was established. The system relies on the delivery of recombinant plasmids into plant leaves by infiltration of agrobacteria. The center forms ΔXT/FT, a glycosylation mutant from Nicotiana benthamiana that synthesizes human type core GnGn structures [7] . Co expressing the proteins of interest with glycan-modifying enzymes generates targeted glycosylation profiles within one week after infiltration of plants. The speed and flexibility of transient expression systems are highly advantageous. The flexibility of the system has been extensively demonstrated by the expression of glycan engineered IgGs [5, 8] within days post agrobacteria infiltration. Markedly, even the production of sialylated IgM, one of the most complex human proteins in both protein assembly and glycosylation was reported [25] . Notably, this was achieved by the simultaneous transient co-expression of up to 13 foreign genes in ΔXT/FT. This is remarkable since the process required the coordinated expression of a series of foreign proteins and enzymes in different subcellular compartments, in a concerted action with the endogenously present cellular protein expression and glycosylation machinery. Apart from the exceptional speed, a transient expression approach is far more flexible than transgenic methods. Depending on the glycan structure desired, individual glycosylation enzymes can be added or omitted to the infiltration mix. Recent advances in synthetic biology facilitate rapid assembly of multigene vectors which enables the delivery of a set of human genes to plant cells in single plasmid [26] (Fig. 2) . Such vectors, which carry up to six genes in a single plasmid, were successfully used by the introduction of the sialylation pathway into plant cells [26] . The multigene vector approach simplifies the entire procedure and facilitates high batch-to-batch consistencies of complex glycan modification steps. (ii) single or multigene vector (MGV) to carry the genes (G) for glycan modelling (e.g. for sialylation; G1-G6). Expression of the glycosylation enzymes in low amounts is normally sufficient to achieve the envisaged glycan structures. If an additional glycan modification is required (e.g. core β1,6-fucosylation and/or branching), plasmids that carry the respective gene(s) can be added (e.g. human α1,6-fucosyltransferase or N-acetylglucosaminyltransferases, indicated as GTX, GTY). Such a modular expression system provides time-efficient and flexible glycan modelling [8] . ΔXF line: glycosylation mutant synthesizing eukaryotic common core structure GnGn Strasser et al. [7] . GT: glycosyltransferase. V1, V2: viral proteins; P: promoter; T: terminator. In summary the plant based system described above provides a reliable platform to generate human antibodies with a controlled glycosylation pattern. Notably, antibody micro heterogeneity in the human serum may comprise several hundred glycoforms, pointing to their manifold functions. The plant based system offers a suitable tool that allows detailed studies of how and to which extend antibodies modulate their activities through this modification. The expected outcomes will provide novel insights about the glycosylation dependent modulation of immunologically related processes and may also have implications for the use of glycan engineering in antibody based therapies.
